Table 1

Baseline characteristics by treatment group

Glargine followed by metforminMetformin alone
AdultYouthAdultYouth
N = 67N = 44N = 65N = 47P value
Anthropometrics
 Age (years)53.5 ± 9.314.9 ± 2.055.2 ± 8.213.9 ± 2.1<0.001
 Female23 (34.3)27 (61.4)37 (56.9)38 (80.9)<0.001
 Race/ethnicity<0.001
  White37 (55.2)13 (29.5)34 (52.3)12 (25.5)
  Black21 (31.3)14 (31.8)19 (29.2)9 (19.1)
  Hispanic (any)5 (7.5)14 (31.8)6 (9.2)20 (42.6)
  Other4 (6.0)3 (6.8)6 (9.2)6 (12.8)
 Weight (kg)104.4 ± 20.0102.0 ± 25.798.1 ± 18.697.7 ± 23.30.274
 BMI (kg/m2)35.0 ± 5.936.5 ± 6.435.0 ± 5.136.9 ± 6.40.201
 BMI percentile98.4 ± 2.598.8 ± 1.30.297
 Waist-to-hip ratio0.97 ± 0.070.93 ± 0.080.95 ± 0.080.94 ± 0.070.029
 Systolic BP (mmHg)127.7 ± 12.0120.7 ± 7.8127.1 ± 13.3119.5 ± 8.7<0.001
 Diastolic BP (mmHg)78.7 ± 9.567.6 ± 7.777.8 ± 11.170.1 ± 7.9<0.001
 BP-lowering medication use (yes)34 (50.7)1 (2.3)35 (53.8)2 (4.3)<0.001
Metabolic phenotype
 HbA1c (%)5.80 ± 0.335.73 ± 0.605.77 ± 0.405.68 ± 0.570.561
 HbA1c (mmol/L)39.9 ± 3.639.2 ± 6.539.5 ± 4.338.6 ± 6.30.561
 IGT50 (74.6)26 (59.1)49 (75.4)28 (59.6)0.105
Lipids
 Total cholesterol (mmol/L)4.21 ± 0.963.86 ± 0.914.51 ± 0.943.72 ± 0.65<0.001
 LDL cholesterol (mmol/L)2.41 ± 0.772.25 ± 0.802.68 ± 0.812.08 ± 0.63<0.001
 Triglycerides (mmol/L)1.36 [0.58, 3.20]1.11 [0.39, 3.14]1.28 [0.50, 3.28]1.17 [0.45, 3.06]0.314
 HDL cholesterol (mmol/L)1.12 ± 0.241.02 ± 0.251.17 ± 0.301.04 ± 0.210.007
 Lipid-lowering medication use (yes)31 (46.3)1 (2.3)20 (30.8)0 (0.0)<0.001
  • Data are n (%), mean ± SD, or geometric mean [95% CI]. P values for nonnormally distributed data based on log-transformed values. P value for ANOVA Type III F test. “Other” for race/ethnicity includes mixed, Asian, American Indian, and other. BP, blood pressure.